Stock CSTL CASTLE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Castle Biosciences, Inc.

Equities

CSTL

US14843C1053

Real-time Estimate Cboe BZX
Other stock markets
 14:02:22 2024-05-03 EDT 		5-day change 1st Jan Change
25.3 USD +10.79% Intraday chart for Castle Biosciences, Inc. +23.40% +16.31%
05-02 Transcript : Castle Biosciences, Inc., Q1 2024 Earnings Call, May 02, 2024
05-02 Earnings Flash (CSTL) CASTLE BIOSCIENCES Posts Q1 Revenue $73M, vs. Street Est of $66.2M MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
BU
Transcript : Castle Biosciences, Inc., Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (CSTL) CASTLE BIOSCIENCES Posts Q1 Revenue $73M, vs. Street Est of $66.2M
MT
Castle Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Castle Biosciences Reports First Quarter 2024 Results
BU
Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year of 2024
CI
Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
BU
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
BU
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
BU
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
BU
Castle Biosciences Insider Sold Shares Worth $441,853, According to a Recent SEC Filing
MT
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
BU
Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress
CI
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
BU
Castle Biosciences Announces Updates to its Board of Directors
BU
Castle Biosciences, Inc. Announces Board Changes
CI
Castle Biosciences, Inc. - Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx-Melanoma Test Result Were Recurrence Free at Three Years
AQ
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
BU
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
BU
Castle Biosciences - Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CSTL Stock
  4. News Castle Biosciences, Inc.